Sutro Biopharma, Inc.’s Post

Innovation is never a solo journey – partnerships are vital to pushing boundaries for the benefit of patients. Watch my interview with Barbara Leyman, Chief Business Development Officer, Sutro Biopharma, to learn more about Astellas’ dynamic and creative partnership approach and how it is helping to advance the next generation of #ImmunoOncology therapies for patients in need. #ChangingTomorrow

Breaking ground in new modalities requires new, creative approaches to partnership. Tomoko Hanadate, Head of R&D Alliances, and Barbara Leyman, Chief Business Development Officer, Sutro Biopharma, share insights on how dynamic deal structures are critical to navigating complex challenges associated with advancing the next generation of #ImmunoOncology therapies.  If you’re an ambitious organization that shares our vision of turning innovative science into VALUE for patients, get in touch: https://lnkd.in/gyp4qwMS #ChangingTomorrow 

Great to see L.E.K. Consulting's report about the 'hub-and-spoke' business model. Nimbus Therapeutics' played a pioneering role in advancing this model (also referenced as the LLC/sub-co model) in biopharma, a structure notably discussed by our founding investor & Chairman, Bruce Booth, from Atlas Venture with great legal counsel from Goodwin. Early blogs about Nimbus' structure from Bruce in 2011 (https://rb.gy/4tk0p0) and 2013 (https://rb.gy/fzo2dp). This innovative approach has enabled us to execute deals with exceptional partners with terms over $7.1B in value, return $4.1B to investors (to-date), and most importantly, advance three programs into the clinic. By leveraging centralized leadership and specialized subsidiaries, we've enhanced focus, operational efficiency, and risk mitigation, driving significant progress in our mission to bring transformative medicines to patients. While all this is great for the business and legal savants, at the end of the day, the business structure can only work if the scientific rationale and supportive data are there - the fundamentals that drive our industry. For more insights of the Hub-and-Spoke model, check out this report by L.E.K. Consulting: https://lnkd.in/e34nEmaU #Biopharma #Innovation #HubAndSpoke #NimbusTherapeutics #PatientCare #LifeSciences

Tomorrow, October 2nd, G&L experts will sit on the 'Maximize Your Drug Asset Value & Commercial Success' panel at Biocom California's offices in San Diego. Dr. Steven Hildemann, MD, PhD, R&D Physician at G&L, will be joined by industry experts including Krishna Allamneni, Executive Vice President, Chief Development Officer at Concarlo Therapeutics, Inc., and @Dr. Michael J. Nowak, Managing Partner, Nowak Ventures, LLC. With a focus on integrating regulatory, clinical, and commercial expertise, this discussion will help you develop novel strategies that set your asset apart. If you're in discovery, pre-clinical, or mid-phase clinical development, this is a must-attend event for gaining insights on increasing valuation at key inflection points. ***Please note, this event is now taking place at Biocom California's offices in San Diego - 10996 Torreyana Rd, San Diego, California 92121*** #HealthcareAdvisors #RegulatoryAffairs #QualityAssurance #ThoughtLeadership #Biopharma

A quite fascinating business model to learn about. From reading more into the the Hub-and-Spoke business model by L.E.K. Consulting, it’s quite clear this model has a few advantages, including: - Enhanced focus benefiting both the parents company and the subsidiaries - All board operational efficiency - Flexible fund raising for both the company/subsidiaries involved and investors, and - A cool way to mitigate risk - which I think might be my favorite benefit of this model! Considering, portfolio de-risking is a constant relevant topic for most pharma strategy leaders and investors, having a business model that limit the risk exposure of the sum and the whole benefits everyone. Also, having business units that are ultra focused on their drug discovery or disease area specialty while also having direct access to external expertise improves efficiency, which in turn drives the acceleration of life changing medicines for patients. Would be curious to see if this is a model that is translatable to big pharma or if the current companies (e.g. Nimbus, and BridgeBio etc.) utilizing this approach can evolve into big pharma. #HubAndSpoke #Pharma

Hear the insights of our very own William & Mary Law School alumnus Stephen Diamond on M&A deal trends in the biotech space. Well done Stephen!

Big Pharma biotech deals bounce back and M&As are in play for high QUALITY, credentialed Cellular Therapy processors and manufacturers. www.medregbio.com

Biopharma success requires more than just great science—it’s about making all the pieces fit. In our next episode, Kymanox Executive Advisor William Monteith shares strategies for aligning operations, quality, and patient focus to foster seamless collaboration with CDMOs. Discover actionable guidance to navigate the complexities of biologics and advanced therapies. Whether you're scaling operations or managing critical partnerships, this conversation is packed with must-hear insights. Episode Hosted by: Chris Adkins Produced by: Earfluence --------- 𝐖𝐚𝐧𝐭 𝐭𝐨 𝐬𝐭𝐚𝐲 𝐜𝐨𝐧𝐧𝐞𝐜𝐭𝐞𝐝 𝐰𝐢𝐭𝐡 𝐊𝐲𝐦𝐚𝐧𝐨𝐱: Follow Us: https://lnkd.in/e35y_dQq Get in Touch: www.kymanox.com Subscribe: https://lnkd.in/eYDXYarv

I thoroughly enjoyed this conversation with William Monteith talking about biotech startups, CDMO partnerships, and more. Check out the full episode - https://lnkd.in/gGdqZYP5

In the ever-evolving healthcare landscape, where decisions shape outcomes and information is crucial, digital channels play a key role in accessing essential product data. We were thrilled to recognize SpringWorks Therapeutics for their exceptional dedication to innovation and outstanding accomplishments, presenting them with the FormularyDecisions Innovation and Impact Award in the Emerging Biopharma category, during AMCP Annual 2024. Watch this interview featuring Zack McCormack, Director of Value and Access at SpringWorks Therapeutics, and Jasmine Knight, Senior Director of Digital Solutions at Cencora, and gain insights into SpringWorks Therapeutics' digital engagement strategy with healthcare decision makers, and the pivotal role played by FormularyDecisions in their digital approach. https://ow.ly/B5VA50SXzlK